However, multivariable mendelian randomization analysis examining the association of genetically proxied ACE inhibition with colorectal cancer risk adjusting for CYB561 expression in the colon was consistent with univariable analyses (OR 1.13, 95% CI: 0.96 to 1.32; P = 0.14). Here, ACE is linked to colorectal cancer.